Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.

Autor: Thorel L; INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France.; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France., Perréard M; INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France.; Department of Head and Neck Surgery, Caen University Hospital, Caen, France., Florent R; ORGAPRED core facility, US PLATON, Université de Caen Normandie, Caen, France., Divoux J; INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France.; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France.; ORGAPRED core facility, US PLATON, Université de Caen Normandie, Caen, France., Coffy S; Biomics, CEA, Inserm, IRIG, UA13 BGE, Univ. Grenoble Alpes, Grenoble, France., Vincent A; CNRS UMR9020, INSERM U1277, CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies, Univ. Lille, CNRS, Inserm, CHU Lille, Lille, France., Gaggioli C; CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), 3D-Hub-S Facility, CNRS University Côte d'Azur, Nice, France., Guasch G; CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Team, Aix-Marseille University, Marseille, France., Gidrol X; Biomics, CEA, Inserm, IRIG, UA13 BGE, Univ. Grenoble Alpes, Grenoble, France., Weiswald LB; INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France. lb.weiswald@baclesse.unicancer.fr.; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France. lb.weiswald@baclesse.unicancer.fr.; ORGAPRED core facility, US PLATON, Université de Caen Normandie, Caen, France. lb.weiswald@baclesse.unicancer.fr., Poulain L; INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France. l.poulain@baclesse.unicancer.fr.; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France. l.poulain@baclesse.unicancer.fr.; ORGAPRED core facility, US PLATON, Université de Caen Normandie, Caen, France. l.poulain@baclesse.unicancer.fr.
Jazyk: angličtina
Zdroj: Experimental & molecular medicine [Exp Mol Med] 2024 Jul; Vol. 56 (7), pp. 1531-1551. Date of Electronic Publication: 2024 Jul 01.
DOI: 10.1038/s12276-024-01272-5
Abstrakt: Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: